NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104025&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors regarding the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The allegations state that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than claimed, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding the FDA's feedback on the drug combination, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024, although participation is not required to be eligible for recovery [4].

NEW YORK, Sept. 20, 2024 /PRNewswire/ --, September 20, 2024 – Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/agenus-lawsuit-sub ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for November 5, 2024 [2]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock value [3].

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103181&from=3 CLASS PERIOD: January 23, 2023 to July ...

Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 - AGENFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their OptionsSeptember 17, 2024 10:06 AM EDT | Source: Faruqi & Faruqi LLPIf you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to dis ...

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. alleging securities fraud that affected investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of their immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - It is alleged that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements by the Company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]. - The firm has over 70 employees and extensive expertise in complex securities litigation [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than previously claimed by the company [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these allegations, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 5, 2024.So What: If you purchased Agenus securities during the Class Period you may ...